SINOVAC Board of Directors Alerts Shareholders to Advantech/Prime Success' New Lawsuit, Which Threatens to Prevent Payment of US$55.00 Special Dividend to All Valid Shareholders

SINOVAC Biotech (SVA) disclosed that Vivo Capital is challenging the distribution of its declared US$55.00 special dividend, leading to a petition for emergency injunctive relief filed against SINOVAC and its paying agent; SINOVAC's board is opposing the action, asserting it is an attempt by Vivo Capital to "double dip" on dividends, having already received over $1.1 billion from an operating subsidiary while other shareholders received nothing. The board intends to file an opposition brief and proceed with a hearing, maintaining that funds for the dividend related to disputed shares are held in escrow, mitigating risk to Vivo Capital.

Analysis

SINOVAC Biotech Ltd. (SVA) faces a significant challenge to its planned US$55.00 per common share special dividend, scheduled for on or about July 9, 2025, due to a Petition for Emergency Injunctive Relief filed by Advantech/Prime Success (representing Vivo Capital, part of the Dissenting Investor Group) on June 12, 2025. This legal action targets SINOVAC and its paying agent, Equiniti, potentially halting the distribution. SINOVAC's Board strongly opposes this Mpetition, characterizing it as "egregious" and "self-serving," alleging the Dissenting Investor Group aims to "double dip" on dividends, having already purportedly received over US$1.1 billion from SINOVAC’s operating subsidiary while other common shareholders received nothing. The Board asserts that funds equivalent to the Dissenting Investor Group's potential dividend allocation from the disputed 2018 PIPE shares are secured in an escrow account managed by an independent third party, mitigating any financial risk to them should the courts rule in their favor. SINOVAC is preparing an Opposition Brief, with a hearing scheduled for Wednesday, June 18, and an expected decision by the following Friday. The situation is marked by a strongly negative sentiment (-0.7) for SVA and a defensive tone from the company, reflecting the considerable uncertainty and potential market impact (score 0.6) on the stock if the dividend payment is indeed obstructed or delayed.

Key Decisions for Investors

• Investors should closely monitor the outcome of the legal proceedings, particularly the hearing on June 18 and the subsequent court decision, as this will directly determine the feasibility and timing of the US$55.00 special dividend.
• The current dispute introduces significant event risk and uncertainty regarding the substantial capital return; shareholders should assess their exposure to SVA considering the potential for a delayed or cancelled dividend payment.
• The ongoing conflict between SINOVAC's Board and the Dissenting Investor Group highlights governance concerns and may signal further volatility, warranting a cautious approach until there is greater clarity on the resolution of these disputes.